Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
730
Views
10
CrossRef citations to date
0
Altmetric
Original Articles

Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

Jan Philipp Bewersdorfa Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAORCID Iconhttps://orcid.org/0000-0003-3352-0902View further author information
ORCID Icon,
Andriy Derkachb Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Lohith Gowdaa Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAView further author information
,
Kamal Menghrajanic Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Susan DeWolfc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYView further author information
,
Josel D. Ruize Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Doris M. Ponced Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Brian C. Shafferd Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Roni Tamarid Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
James W. Youngd Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;f The Rockefeller University, New York, NY, USAView further author information
,
Ann A. Jakubowskid Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Boglarka Gyurkoczad Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-2933-2119View further author information
ORCID Icon,
Alexander Chang Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Wenbin Xiaog Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Jacob Glassc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Amber C. Kingh Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Sheng F. Caic Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Anthony Daniyanc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Christopher Famularec Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYView further author information
,
Bernadette M. Cuelloc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYView further author information
,
Nikolai A. Podoltseva Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAView further author information
,
Mikhail Roshalg Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Sergio Giraltd Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Miguel-Angel Peralesd Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Stuart Seropiana Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAView further author information
,
Christina Chod Weill Cornell Medical College, New York, NY, USA;e Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Amer M. Zeidana Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAView further author information
,
Thomas Prebeta Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USAORCID Iconhttps://orcid.org/0000-0002-6872-625XView further author information
ORCID Icon,
Eytan M. Steinc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Martin S. Tallmanc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
,
Aaron D. Goldbergc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USAView further author information
&
Maximilian Stahlc Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;d Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
View further author information
 show all
Pages 3394-3401 | Received 09 Jul 2021, Accepted 31 Jul 2021, Published online: 03 Sep 2021

References

  • Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208–217.
  • Devillier R, Crocchiolo R, Etienne A, et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma. 2013;54(6):1228–1234.
  • Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730–3738.
  • Byrne M, Danielson N, Sengsayadeth S, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95(9):1006–1014.
  • Amit O, On YB, Perez G, et al. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial. Ann Hematol. 2021;100(3):817–824.
  • Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the german cooperative transplant study group. Ann Hematol. 2021;100(4):959–968.
  • Joshi M, Cook J, McCullough K, et al. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J. 2021;11(3):49.
  • Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33(12):2795–2804.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
  • Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma. 2020;61(9):2221–2225.
  • Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019;98(8):1927–1932.
  • Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5(5):1552–1564.
  • DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736.
  • Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521.
  • Sandhu KS, Dadwal S, Yang D, et al. Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2020;26(12):e322–e327.
  • Kennedy VE, Hui G, Gaut D, et al. Hypomethylating agents in combination with venetoclax as a bridge to allogeneic transplant in acute myeloid leukemia. Blood. 2020;136(Supplement 1):32–33.
  • Pollyea DA, Winters A, Jordan CT, et al. Allogeneic transplant improves AML outcomes compared to maintenance venetoclax and azacitidine following response to initial venetoclax and azacitidine therapy. Blood. 2020;136(Supplement 1):24–24.
  • DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791–803.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.